ARRS: MASS Criteria, LDH Predict Survival in Melanoma
Wednesday, April 17, 2013 (Last Updated: 04/18/2013)
WEDNESDAY, April 17 (HealthDay News) -- For patients with metastatic melanoma on bevacizumab, an index combining Morphology, Attenuation, Size, and Structure (MASS) criteria response on the first post-therapy computed tomography (CT) with serum lactate dehydrogenase (LDH) levels predicts survival, according to a study presented at the annual meeting of the American Roentgen Ray Society, held from April 14 to 19 in Washington, D.C.
Andrew Smith, M.D., from the University of Mississippi Medical Center in Jackson, and colleagues conducted a secondary analysis of CT and clinical data from 46 patients with metastatic melanoma on bevacizumab therapy to identify parameters that predict progression-free survival (PFS) and overall survival (OS).
The researchers found that the median PFS was four months and median OS was 14 months for the entire cohort. MASS criteria response on the first post-therapy CT was strongly predictive of PFS and OS in multivariate analysis. High baseline serum LDH correlated with significantly reduced PFS and OS. An index combining LDH and MASS criteria response on the first post-therapy CT demonstrated high accuracy for predicting PFS of more than nine months and OS of more than two years in receiver operating curve analyses (area under the curve, 0.97 and 0.87, respectively).
"What was surprising to us was that the accuracy for predicting both progression-free and overall survival is substantially increased when MASS Criteria findings are combined with data from serum LDH levels," Smith said in a statement.
Hematology & Oncology